Veterinary Monoclonal Antibodies Companies

The global veterinary monoclonal antibodies market is projected to reach USD 3.06 billion by 2030, from USD 1.70 billion in 2025, with a CAGR of 12.4%. This growth is primarily driven by the rising number of companion animals and pet ownership, as well as growing concerns about chronic diseases in animals. The market is further supported by increased adoption of pet insurance, higher healthcare spending for animals, and heightened awareness campaigns by the government and animal welfare groups.

The prominent players in the veterinary monoclonal antibodies market include Zoetis Services LLC (US), Elanco (US), and Merck & Co., Inc. (US). These players are continuously developing new products and adopting strategies like partnerships and expansions to strengthen their market reach. For instance, in September 2024, Zoetis Services partnered with the Arthritis Foundation (US) to raise awareness about osteoarthritis (OA) pain in pets. Through this partnership, the company promotes Librela, its FDA-approved, once-monthly injectable monoclonal antibody for dogs, as a breakthrough therapy for managing OA pain, thereby improving mobility and quality of life. In August 2024, Elanco announced a USD 130 million investment and a 25,000-sq-ft expansion of its biologics facility in Elwood, Kansas. This upgrade will double production capacity to support manufacturing of its Canine Parvovirus Monoclonal Antibody (CPMA), the first USDA conditionally approved mAb for parvovirus, and prepare the plant for upcoming mAb therapies.

To know about the assumptions considered for the study download the pdf brochure

Zoetis Services LLC (US)

Zoetis Services discovers, develops, manufactures, and commercializes vaccines and medicines for livestock and companion animals. The company operates through three segments: Companion Animals, Livestock, and Contract Manufacturing & Human Health. It offers dermatology products for animals through the Companion Animals and Livestock segments. The company operates in 70 countries, and its products are sold in over 120 countries through its distribution networks. Its key subsidiaries include Alpharma Animal Health Company (US), Fort Dodge Asia Exports, Inc. (US), and Jilin Pfizer Guoyuan Animal Health Co., Ltd. (China). Zoetic Services also heavily invests in product launches and developments. For instance, the company’s Librela (bedinvetmab injection) targets nerve growth factor (NGF) to significantly improve dog mobility and comfort, offering an innovative alternative to NSAID therapy.

Elanco (US)

Elanco is among the global leaders in animal health, dedicated to delivering innovative products and services that prevent and treat diseases in farm animals and pets. With a portfolio of approximately 200 brands, the company provides solutions for various species, including dogs and cats under pet health and cattle, poultry, swine, sheep, and aqua under farm animal care. It primarily operates through one segment but organizes its sales and operations into three categories: Pet Health, Farm Animal, and Contract Manufacturing. A key innovation area for Elanco is monoclonal antibody (mAb) therapies. In 2023, the company launched the world’s first USDA conditionally approved mAb treatment for canine parvovirus. With ongoing investments in mAb R&D and expanded biologics manufacturing capabilities, it is advancing its pipeline for future antibody-based therapies.

Merck & Co., Inc. (US)

Merck is a prominent player in healthcare, delivering innovative solutions such as prescription medications, vaccines, biologic therapies, and animal health products. The company operates through two divisions: Pharmaceuticals and Animal Health. Its Animal Health division offers monoclonal antibody therapies for companion animals. Merck has a presence in over 140 countries and has 25 manufacturing facilities across the Americas, Europe, and Asia Pacific. The company’s robust R&D network includes 16 research centers in the US, Spain, Germany, Norway, South Africa, India, Australia, Singapore, and Japan. In  May 2025, Merck Animal Health expanded its manufacturing and R&D facilities in De Soto, Kansas, with a USD 895 million investment. This expansion aims to boost production capacity and innovation, particularly supporting biologics and vaccine development, including monoclonal antibody therapies.

Market Ranking

The veterinary monoclonal antibodies market is competitive, with the top players being Zoetis Services LLC (US), Elanco (US), and Merck & Co., Inc. (US). The competition among the leading players is high, and most focus on establishing partnerships with others to ensure a stable market share. The market is dominated by key players with a strong global footprint and well-established supply and distribution chains in developed regions such as North America and Europe.

Related Reports:

Veterinary Monoclonal Antibodies Market by Animal Type (Canine, Feline, Swine), Product (Cytopoint, Librela, Solensia), Therapy Area (Dermatology, Infectious, Osteoarthritis, Pain, Oncology, Others), Route of Administration - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com